AFP and hepatocellular carcinoma: Currently, the most widely used biomarker for early detection is AFP; however, a large number of AFP-negative HCC patients exist (60% sensitivity) [7], making the need for more efficient novel prognostic biomarkers imminent, considering HCC is mostly lethal because it is extremely difficult to diagnose in early stages.